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Abstract
Patients with Alzheimer’s disease after an initial response to cholinesterase inhibitors may complain a later lack of efficacy.
This, in association with incident neuropsychiatric symptoms, may worsen patient quality of life. Thus, the switch to another
cholinesterase inhibitor could represent a valid therapeutic strategy. The aim of this study was to investigate the
effectiveness of the switch from one to another cholinesterase inhibitor on cognitive and affective symptoms in mild to
moderate Alzheimer disease patients. Four hundred twenty-three subjects were included from the EVOLUTION study, an
observational, longitudinal, multicentre study conducted on Alzheimer disease patients who switched to different
cholinesterase inhibitor due either to lack/loss of efficacy or response, reduced tolerability or poor compliance. All patients
underwent cognitive and neuropsychiatric assessments, carried out before the switch (baseline), and at 3 and 6-month
follow-up. A significant effect of the different switch types was found on Mini-Mental State Examination score during time,
with best effectiveness on mild Alzheimer’s disease patients switching from oral cholinesterase inhibitors to rivastigmine
patch. Depressive symptoms, when measured using continuous Neuropsychiatric Inventory values, decreased significantly,
while apathy symptoms remained stable over the 6 months after the switch. However, frequency of both depression and
apathy, when measured categorically using Neuropsychiatric Inventory cut-off scores, did not change significantly during
time. In mild to moderate Alzheimer disease patients with loss of efficacy and tolerability during cholinesterase inhibitor
treatment, the switch to another cholinesterase inhibitor may represent an important option for slowing cognitive
deterioration. The evidence of apathy stabilization and the positive tendency of depressive symptom improvement should
definitively be confirmed in double-blind controlled studies.
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Introduction
Alzheimer’s disease (AD) is a severe chronic neurodegenerative
disease characterized by progressive cognitive impairment, func-
tional decline and neuropsychiatric symptoms [1].
The phenomenology of AD is greatly variable due to the
influence of many factors, such as comorbid non-degenerative
medical diseases, concomitant pharmacological treatments, envi-
ronmental variables and progression of dementia itself [2]. All
these factors, in association with treatment response, determine a
high heterogeneity of clinical manifestations and very often make it
difficult to manage patients [3]. Thus, the effectiveness of AD
treatment, especially with regard to neuropsychiatric phenome-
nology, is of fundamental importance not only to reduce patient
suffering and caregiver burden but also to contain economic costs
of the disease [4].
Cholinesterase inhibitors (ChEIs), the most effective drugs
available at present for treatment of mild to moderate AD, can
stabilize cognitive symptoms for a one to three year period, but
they are not able to modify the progression of the disease [5].
There is also preliminary evidence that they may improve some
neuropsychiatric symptoms [6]. Unfortunately, the therapeutic
response to ChEIs is less satisfying in the long-term period and
some patients adhere to prescribed treatment for only a short time.
Poly-pharmacotherapy due to comorbid diseases, side effects
particularly caused by high dosages of oral ChEIs, and initial or
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delayed lack of efficacy are some reasons of reduced compliance
[7].
One of the possible strategies to improve compliance and
effectiveness in patients no longer responding to initial treatment is
the switch from one to another ChEI [7]. To date, few studies
have focused on ChEI switch and the vast majority of results have
concentrated on cognitive impairment and described a switch
from donepezil to rivastigmine, suggesting that patients non
responder to donepezil may benefit from the switch [8,9]. In
particular, the switch from oral to transdermal formulation was
demonstrated to be effective on cognitive symptoms and to have a
good safety profile [10].
Furthermore, little is known on the effects of a switch on
neuropsychiatric symptoms. In particular, no data are available on
the effectiveness on the two more common symptoms in AD,
which is depression and apathy. Thus, we collected data from the
‘‘bEhaVioral symptOms in Alzheimer’s disease: evaLUation of
paTIents treated with chOliNesterase inhibitors’’ (EVOLUTION)
study in order to describe changes in cognitive and affective
domain severity in mild to moderate AD patients enrolled in a
switch ChEI study for lack or loss of efficacy and tolerability/
compliance.
Materials and Methods
Ethics Statement
The study was approved by the ethical committees of the three
coordinating centres, that is: IRCCS Fondazione Santa Lucia,
Roma, Universita` of Firenze, and Universita` di Brescia, and by the
ethical committees of all the participating memory clinics of the
EVOLUTION study group, that is: Ospedale Garibaldi, Catania,
Ospedale Civile Guzzardi, Ragusa, Ospedale Mazzini, Teramo,
Ospedale dell’Annunziata, L’Aquila, Ospedale Civile San Pio da
Pietralcina, Chieti, AORN Cardarelli, Napoli, Policlinico Uni-
versitario Tor Vergata, Roma, AORN S.Sebastiano, Caserta,
Ospedale San Salvatore, L’Aquila, Universita` degli Studi di
Torino Clinica Neurologica, Ospedale San Filippo Neri, Roma,
ASL RM F, Roma, Ospedale S. Giovanni Calibita, FBF, Roma,
Ospedale Sant’Anna, Como, Ospedale Niguarda Ca’ Granda,
Milano, Ospedale Santa Scolastica, Frosinone, Ospedali Riuniti,
Bergamo, Ospedale Santa Corona, Savona, Policlinico Martino,
Messina, Ospedale San Pietro FBF, Roma, Policlinico Consor-
ziale, Bari, Azienda Ospedaliera di Verona, Ospedale Civile
Agnelli, Torino, Ospedale Evangelico Valdese, Torino, Distretto
2, Modena, Ospedali Riuniti, Ancona, Ospedale Galliera Mura
delle Cappuccine, Genova, Policlinico SS Annunziata, Chieti,
Azienda Ospedaliera Padova, AUOP Policlinico Giaccone,
Palermo, Ospedale degli Infermi, Rimini, Ospedale Manzoni,
Lecco, Ospedale Centrale di Bolzano, Ospedale Morgagni
Pierantoni, Forlı` Cesena. All included subjects and/or caregivers
signed an informed consent form prior to enrolment, in
accordance with the Helsinki Declaration.
The EVOLUTION observational study meets the ethical-
administrative Italian legislation at the time of the study
administrative process start (03.11.2009) according to ‘‘CM 6
02.09.2002, GU 214 12.09.2002’’ and ‘‘D 29.03.2008’’ of the
Agenzia Italiana del Farmaco (AIFA – Italian Medicines Agency)
GU 76 31.03.2008, Art 10 (Procedures for Observational Studies).
Methods
The EVOLUTION study is an observational, longitudinal,
multicentre study conducted in 38 outpatient memory clinics
throughout Italy. To be eligible in the study the subjects met the
following inclusion criteria: 1) diagnosis of probable AD according
to the National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and Related
Disorders Association (NINCDS-ADRDA) criteria [11]; 2) mild to
moderate severity of dementia, defined as Mini-Mental State
Examination (MMSE) [12] score ranging from 26 to 10; 3) onset
of symptoms occurred at least 6 months before the date of the
enrolment; 4) patient treated with ChEI for at least 6 months,
performing for the first time a switch to another ChEI due to lack
of response (i.e., lack or loss of efficacy defined as a reduction of at
least 2 points of MMSE score in the last 6 months) [13] and/or
reduced compliance (due to side effects or no adherence to
recommended oral dosing regimen); 5) vision and hearing
sufficient for compliance with testing procedures; 6) presence of
caregiver able to understand all testing procedures. Exclusion
criteria were: 1) hospitalization (i.e., to be an inpatient); 2) history
of head trauma or other neurologic diseases apart from AD; 3)
clinically significant or unstable major medical illnesses (e.g.,
diabetes, obstructive pulmonary disease or asthma, hematologic
disorders, active gastrointestinal, renal, hepatic, endocrine or
cardiovascular disorders); 4) history of cancer within the last 5
years; 5) dementia other than probable AD; 6) known or suspected
history of alcoholism or drug dependence and abuse during
lifetime.
All included patients underwent cognitive and neuropsychiatric
assessments, carried out before the switch (baseline), and at 3 and
6-month follow-up. Trained psychologists and neuropsychologists
performed all evaluations.
The global cognitive impairment was assessed by the MMSE
[12], a widely used neurocognitive screening test measuring
orientation, language, verbal memory, attention, visuospatial
function and mental control. MMSE score ranges in 11 different
items and lower scores mean higher cognitive impairment. Based
on MMSE total score the patients were classified as having mild
(MMSE = 18–26) or moderate (MMSE = 10–17) AD.
The Neuropsychiatric Inventory (NPI) was used to assess the
frequency and severity of neuropsychiatric symptoms in 12
domains: delusions, hallucinations, agitation, depression, anxiety,
euphoria, apathy, disinhibition, irritability, aberrant motor
behavior, nighttime behavior disturbances, appetite and eating
abnormalities [14]. The severity and frequency of each symptom
were scored on the basis of structured questions administered to
the caregiver. Frequency was rated from 1 (occasionally) to 4 (very
frequently) and severity from 1 (mild) to 3 (severe). If the symptom
was absent, a score equal to zero was given. The multiplication of
frequency and severity was used as symptom composite score, with
a range from 0 to 12. We used two different methods to investigate
neuropsychiatric phenomena. First, we measured continuous
scores of NPI. Second, NPI symptoms were also categorized
(Yes/No) on the basis of criteria useful for clinical purposes in AD
patients [15]. In particular, symptom composite score$4 indicates
the presence of clinically relevant symptoms, typically associated
with therapeutic intervention, a score between 1 and 3 charac-
terizes mild symptoms usually not requiring specific treatment,
and a score of 0 means no symptoms [16,17].
For this study, two different switch types were considered: 1)
from non-rivastigmine oral ChEI (i.e. donepezil and galantamine)
to rivastigmine transdermal patch, and 2) from rivastigmine patch
to other non-rivastigmine oral ChEI. According to the treatment
guidelines for AD, the practice was that patients switched
immediately from other ChEI to rivastigmine transdermal patch
4.6 mg/24 h; one month after the switch, they were given a dose
increase to 9.5 mg/24 h and remained on this dosage, unless they
experienced adverse events. Patients who experienced adverse
events had rivastigmine patch dosage reduced to 4.6 mg/24 h.
Cognitive and Affective Changes after ChEI Switch
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About the second switch type, only data on patients switching from
rivastigmine transdermal patch to donepezil were considered: the
practice was that patients switched from rivastigmine transdermal
formulation to 5 mg/24 h oral donepezil following a 7 days
withdrawal period. After one month donepezil was titrated to
10 mg/die and maintained at this dosage through the study, unless
adverse events appeared. Patients who experienced adverse events
had donepezil dosage reduced to 5 mg/24 h.
Differences among variables at baseline were measured by
means of chi-square for categorical variables and Analysis of
Variance (ANOVA) with Bonferroni post-hoc test (significance
corrected for multiple comparisons) for continuous variables. For
the aims of this study we focused our neuropsychiatry analyses
only on the two more common symptoms in AD, that is depression
and apathy, as measured by NPI. Thus, a series of 3 repeated
measures ANOVAs with MMSE, NPI depression/dysphoria or
NPI apathy scores as dependent variables and categories of AD
severity (mild/moderate) and switch type (oral/patch) as indepen-
dent variables were used to assess cognitive and affective (apathy-
depression) changes during time between groups with different
switches. The level of statistical significance was defined as p,
0.05.
Results
Patients’ Characteristics, Comorbid Illnesses, and
Concomitant Treatments
Of the overall group of the 635 subjects enrolled in the
EVOLUTION study (mean age 7767 SD years; 60% women),
423 patients satisfied the inclusion/exclusion criteria of the present
sub-analysis and were here considered (mean age 7865 SD years;
60% women).
Based on the type of switch and on the severity of AD, four
groups of patients were identified: 1) switch from oral ChEI to
rivastigmine patch with mild AD; 2) switch from oral ChEI to
rivastigmine patch with moderate AD; 3) switch from rivastigmine
patch to oral ChEI with mild AD; and 4) switch from rivastigmine
patch to oral ChEI with moderate AD.
Sociodemographic features of the four groups are summarized
in Table 1.
Reasons of the switch therapy were: loss of ChEI efficacy
(n = 175, 41.4%), lack of response (n = 122, 28.8%), reduced
tolerability (n = 60, 14.2%), and poor compliance (n = 42, 9.9%).
In 24 (5.7%) patients other causes determined the switch (i.e.
patient/caregiver request, no dose regimen reached in previous
treatment). Thus, in more than 70% of the included AD patients
causes of cognitive decline during the last 6 months before the
switch were lack of efficacy or response.
Comorbidity for other medical illnesses was present in about
75% of the whole patient group, and no significant differences
emerged among the four subgroups. The most frequent comorbid
illnesses were hypertension (n = 209, 49.4%), dyslipidemia (n = 67,
15.8%) and not complicated diabetes (n = 64, 15.1%); other
concomitant stable illnesses, such as gastrointestinal, renal,
pulmonary and metabolic diseases, accounted for less than 5%
of patients.
One hundred eighty six (44%) patients reached the maximum
dosage of ChEI (10 mg for oral donepezil, 9.5 mg for rivastigmine
patch), with no significant difference among the four groups.
Megadose regimen was not used in any patient. Patients switching
to oral ChEI, with moderate AD, had significant longer duration
of maximum dosage (147.8 days 635.7 SD) than those switching
to patch ChEI, both with mild AD (104.8 days 639.6 SD;
F = 7.278; df = 3; p,0.0001) and with moderate AD (111.3 days
639.1 SD; F = 7.278; df = 3; p = 0.002), while no significant
difference was found with patients switching to oral ChEI with
mild AD (138.6 days 642.4 SD). Only 11 patients (3%) belonging
to both groups switching to patch ChEI reported clinically
significant side effects, mainly immediately after the dosage
increase: cutaneous rush (8 patients), malaise (1 patient), irritability
(1 patient) and nausea (1 patient). In 6 patients the clinician made
a temporary drug interruption with restart at lower dosages, in 2
patients a lower dosage was prescribed without washout period, in
3 patients no action was taken.
At the baseline visit, 36 (8.5%) patients of the whole patient
group were treated with meantime and there was a significant
Table 1. Sociodemographic and clinical characteristics of the four switch subtypes.
Switch from oral to patch ChEI Switch from patch to oral ChEI
Mild AD Moderate AD Mild AD Moderate AD
(n=165) (n=201) (n =22) (n =35)
Mean 6 SE Mean 6 SE Mean 6 SE Mean 6 SE
Age (years) 77.260.4 78.760.4 78.261.4 79.561
Female nu (%) 85 (51.5) 134 (66.7) 12 (54.6) 25 (71.4)
Education nu (%)
none 16 (9.7) 37 (18.4) 2 (9.1) 5 (14.3)
primary education 84 (50.9) 119 (59.2) 12 (54.6) 22 (62.9)
lower secondary education 32 (19.4) 23 (11.4) 4 (18.2) 2 (5.7)
upper secondary education 24 (14.6) 15 (7.5) 2 (9.1) 4 (11.4)
tertiary education 9 (5.5) 7 (3.5) 2 (9.1) 2 (5.7)
MMSE score 2160.2 14.360.2 20.160.4 13.960.4
NPI depression/dysphoria score 1.760.2 2.260.2 1.560.5 1.760.5
NPI apathy score 3.460.3 4.060.3 3.760.8 4.560.6
AD=Alzheimer’s disease; ChEI = cholinesterase inhibitor; MMSE =Mini-Mental State Examination; NPI =Neuropsychiatric Inventory; SE = standard error.
doi:10.1371/journal.pone.0089216.t001
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difference among the four groups: patients switching to oral ChEI
had higher frequency (mild AD: n = 3, 13.6%; moderate AD:
n = 7, 20%) than those switching to patch ChEI (mild AD: n = 7,
4.2%; moderate AD: n = 19, 9.5%) (Chi-Square = 10.766; df = 3;
p = 0.013). The mean daily dosage of memantine was 15.9 mg
65.1 SD). The only changes in memantine treatment during the
6-month observational period were made, in a total of 10 (2.4%)
subjects, at the 3-month follow-up visit. In particular, 5 patients (2
switching to patch ChEI with mild AD, 1 switching to patch ChEI
with moderate AD, and 2 switching to oral ChEI with moderate
AD) had a new prescription of memantine, while 5 patients (2
switching to patch ChEI with mild AD, 3 switching to patch ChEI
with moderate AD, and 1 switching to oral ChEI with mild AD)
withdrawn memantine due to side effects. Thus, these few changes
in memantine prescription during the six-month period of
observation may be considered irrelevant for the results of this
study.
At the baseline visit, 126 patients (29.8%) were under
psychotropic medications with no statistically significant differenc-
es among the four groups (Chi-Square = 2.844; df = 3; p = 0.416).
The psychotropic agents more frequently used were antidepres-
sants (n = 88, 20.8%) and antipsychotics (n = 49, 11.6%). benzo-
diazepines or hypnotics were prescribed in 17 patients (4%).
Cognitive and Neuropsychiatric Symptoms
At baseline no significant differences were found among four
groups of patients identified according to switch modality (from
oral to patch ChEI, from patch to oral ChEI) and dementia
severity (mild AD, moderate AD) except for MMSE scores: as
expected, patients with moderate AD had significant lower MMSE
scores than those with mild AD (F = 389.184; df = 1,419; p,
0.0001). Moreover, patients switching from oral to patch ChEI
had slightly higher MMSE scores than patients switching from
patch to oral ChEI (F = 3.910; df = 1,419; p,0.0486) (see Table 1).
Mild AD patients switching from rivastigmine patch to non-
rivastigmine oral ChEI (n = 22) had a mean MMSE score of 20.1
(60.4 SE) at the baseline, decreasing to 17.5 (60.6 SE) at 6-month
follow-up (delta = 2.6) in comparison of mild AD patients with
opposite switch (n = 165) who decreased from 21.0 (60.2 SE) to
19.8 (60.3 SE) (delta = 1.2). MMSE score changes in patients with
moderate AD were overlapped between groups with different
switch modalities (see Figure 1).
There was a significant change in MMSE score during time
(F = 11.4; df = 2,838; p,0.0001; lambda = 22.795; power = 0.997),
a significant interaction between MMSE score change and
categories of AD severity (F = 3.0; df = 2,838; p = 0.049; lamb-
da = 6.067; power = 0.579), and a significant interaction between
MMSE score change and groups of different switches (F = 10.7;
df = 2,838; p,0.0001; lambda = 21.338; power = 0.995).
NPI depression/dysphoria continuous scores decreased signif-
icantly during time (F = 4.0; df = 2,838; p = 0.019; lambda = 8.004;
power = 0.717) from 1.9 (60.1 SE) to 1.4 (60.1 SE), with no
interaction effect (see Figure 2).
NPI apathy continuous scores were very stable during time
(F = 1.6; df = 2,838; p = 0.2; lambda = 3.218; power = 0.328) with
no variation in score from 3.8 (60.2 SE) to 3.8 (60.2 SE), with no
interaction effect (see Figure 3).
Detailed frequencies of categories of depression and apathy at
the baseline and follow-up are described in Table 2. In particular,
according to NPI categorization, clinically relevant symptoms of
depression (score$4) were present in 111 patients (26.2%) at
baseline and in 84 patients (19.9%) at 6-month follow-up. In
addition, apathy clinically relevant symptoms (score$4) were
present in 207 patients (48.9%) at baseline and in 200 patients
(47.3%) at 6-month follow-up. Differences in frequency from
baseline to 6-month follow-up for each category of depression and
apathy did not reach statistical significance either in the subgroups
of mild and moderate AD or in the total groups (p.0.1 for all
comparisons) (see Table 2).
Discussion
Results of this observational study suggest that in AD patients
no more responsive to initial treatment, with reduced tolerability
and/or compliance and loss of at least 2 points at MMSE score in
the last 6 months, the switch from oral ChEI (donepezil or
galantamine) to transdermal rivastigmine patch formulation may
reduce the progression of global cognitive impairment, particularly
in mild AD patients. In addition, stabilization in the frequency of
clinically relevant depression and apathy phenomena may be
achieved by using switch procedure, independently from the
switch type and the illness severity. There is also a preliminary
suggestion that improvement in continuous values of depressive
symptoms may be achieved, but this point needs of further
validation.
Several studies have been conducted in order to monitor and
describe the utilization of ChEIs and their switch in the clinical
practice. A recent retrospective study, carried out on a US
administrative database of 3177 AD patients treated at least once
with ChEI, showed that the switch from one ChEI to another one
ranges from 14.5% to 21.5%, with a mean time of treatment with
the same drug ranging between 226 and 206 days for the three
different ChEIs (donepezil, rivastigmine and galantamine) [18].
Previous studies, always on administrative databases, showed that
approximately 30% of patients treated with donepezil or
rivastigmine drop out treatment or perform a switch to another
ChEI within 60 days after the start of the first therapy with ChEI
[19]. Some observational studies highlighted that the switch from
other ChEIs to rivastigmine leads to evident cognitive benefits and,
in some cases, to tolerability improvement of the new treatment
[13,20]. More recently, the switch from oral to transdermal ChEI
formulation has been demonstrated to be effective and with a good
safety profile [10]. Tian et al, in a retrospective study performed
on 772 AD patients initially treated with donepezil, showed that
the switch to rivastigmine transdermal patch resulted in a greater
adherence to the treatment regimen compared to oral treatment
[21]. This result was more evident in patients who carried the
switch in the first year after they started therapy with oral
donepezil [21]. Moreover, the switch from a ChEI in oral
formulation to rivastigmine transdermal patch can be made
immediately without washout period [22].
The results of our study enforce all these previous data on the
favourable effect of the switch from oral ChEI to rivastigmine
transdermal patch. Moreover, the advantage of ChEI switch is
more evident if we consider that in the last 6 months before
baseline visit almost 70% of patients had a reduction of at least 2
points of MMSE score, while after the switch a stabilization of
cognitive functions was present. Indeed, we found that patients
with AD (particularly of mild severity) who switched from non-
rivastigmine oral ChEI to rivastigmine transdermal formulation
had lower progression of cognitive impairment than those
switching from transdermal to oral formulation. One of the
possible explanation of the positive effect of the switch from non-
rivastigmine oral to rivastigmine transdermal ChEI is that
transdermal formulation allows a continuous release of the active
compound, thus avoiding fluctuations in plasma levels that are
typical of the oral formulation, moreover it limits the typical side
effects of oral ChEIs and increases patient compliance [10]. The
Cognitive and Affective Changes after ChEI Switch
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Figure 1. Changes of global cognitive level during ChEI switch. An analysis of variance with repeated measures indicates that the
longitudinal course of global cognitive level (i.e. MMSE score changes during a 6-month period) in mild to moderate AD patients performing for the
first time a switch to another ChEI due to lack of response/reduced compliance, is more favourable when switching from oral ChEIs to rivastigmine
patch, with best effectiveness in mild AD patients (see the results section for statistic details). SE = Standard Error; MMSE=Mini-Mental State
Examination.
doi:10.1371/journal.pone.0089216.g001
Figure 2. Changes of NPI depression/dysphoria score during ChEI switch. An analysis of variance with repeated measures indicates that the
longitudinal course of depressive symptoms (i.e. NPI depression score changes during a 6-momth period) in mild to moderate AD patients
performing for the first time a switch to another ChEI due to lack of response/reduced compliance, improves independently from AD severity and
switch type (see the results section for statistic details). SE = Standard Error; NPI =Neuropsychiatric Inventory.
doi:10.1371/journal.pone.0089216.g002
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rivastigmine effectiveness on patients no more responsive to other
ChEI could be explained also from a molecular point of view.
Indeed, rivastigmine has pharmacological properties that distin-
guish it from other ChEI. First, rivastigmine has a selective effect
on G1 enzymatic isoform of acetylcholinesterase, that predomi-
nates in patients with AD [23]; second, rivastigmine inhibits not
only acetylcholinesterase but also butyrylcholinesterase that is able
of compensating for acetylcholinesterase function in case of
deficiency [24]; third, the low protein binding property of
rivastigmine is indicative of reduced drug interactions [23] and
higher compliance, especially in elderly AD patients who typically
have concomitant illnesses and take multiple medications [25].
Finally, the cognitive effect of rivastigmine was strongly evident
on patients with mild illness severity at the baseline, possibly
because of the rivastigmine effect on butyrylcholinesterase. We can
speculate on mechanisms under this effect. Indeed, in two dated
papers has been hypothesized that butyrylcholinesterase might
play a role in the aggregation of beta-amyloid that occurs
especially in the early stages of AD [26,27]. In addition, results
of two recent preclinical studies more clearly indicate possible
mechanisms of beneficial effects of rivastigmine treatment,
describing: a) protection from change of neuronal morphology
and presynaptic protein markers in degenerating primary embry-
onic cerebrocortical cultures [28], and b) enhancement of
neuronal secreted Abeta Precursor Protein (APP), wich is
protective against neuronal apoptosis, and shift APP processing
toward the a-secretase pathway, both phenomena which mirror
the trend of synaptic proteins, and metabolic activity [29]. Further,
on the basis of preliminary data on structural brain changes in AD
patients treated with ChEI [30], we could also speculate that
treatment with dual ChEI, such as rivastigmine, may decrease the
rate of brain atrophy by the reduction of amyloid plaque
neurotoxicity due to butyrylcholinesterase inhibition. This effect,
if present, should be more evident in patients at the early stage of
the disease.
Another interesting result highlighted from the EVOLUTION
study is the improvement of depressive symptoms (limited to the
analysis of continuous values of NPI scores) and the stabilization of
apathy symptoms within 6 months after switch procedures. This
effect was observed independently from the switch type and the
illness severity. Some pieces of evidence in the literature suggest
that depression in AD has peculiar features and it is closely linked
to the primary neurodegenerative disease. In fact, post-mortem
studies demonstrated that patients with AD and history of major
depression show an increased number of neurofibrillary tangles
and beta-amyloid plaques, the characteristic neuropathological
markers of AD, in hippocampus [31]. Furthermore, in patients
with major depression at the time of AD clinical diagnosis, the
presence of such markers is further increased [31]. These data
clearly explain the negative results of recent studies focused on
therapeutic efficacy of antidepressants in patients with AD [32,33]
and, on the other hand, could justify an important role of the
drugs currently used for the treatment of cognitive impairment on
the control of depressive symptoms in patients with AD. In this
regard, a recent study evaluated the effect of rivastigmine
transdermal formulation in patients with AD and comorbid major
depressive episode (MDE), never treated before with antidepres-
sants [34]. After six months of treatment with rivastigmine
transdermal patch a significant reduction of the occurrence of
MDE and a reduction of the severity of depressive symptoms were
evident. In addition, this pattern was more evident in patients
largely responsive to treatment with rivastigmine, indicating a
possible positive effect of the drug on AD patients with depressive
phenomenology [34].
As far to apathetic symptoms, no clinical studies on the possible
positive effect of ChEI switch have yet been conducted. Moreover,
Figure 3. Changes of NPI apathy score during ChEI switch. An analysis of variance with repeated measures indicates that the longitudinal
course of apathy symptoms (i.e. NPI apathy score changes during a 6-momth period) in mild to moderate AD patients performing for the first time a
switch to another ChEI due to lack of response/reduced compliance, do not change over time (see the results section for statistic details).
SE = Standard Error; NPI =Neuropsychiatric Inventory.
doi:10.1371/journal.pone.0089216.g003
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the association between apathy and dementia has been largely
demonstrated in recent studies [35,36], so as some authors
postulated that apathy should be considered a mixed cognitive/
psychiatric disturbance related to AD neurodegeneration [37].
Thus, apathetic symptoms, as well as cognitive symptoms, could
benefit from switch to a more effective ChEI.
Some limitations of the present study deserve to be mentioned.
First, this is an observational study with the well-known limitations
derived from this type of study. In particular, we did not include a
control group of patients with no switch from one ChEI to
another. Thus, further double blind controlled studies, including
patients steadily treated with antidementia drugs, should confirm
results here reported. Second, the sample of patients who switched
from oral to transdermal ChEI was much greater than those
performing the opposite switch. Although this difference may
potentially influence our results, it is possible that clinicians used
more frequently the oral to transdermal ChEI switch because their
feelings of a better effectiveness and/or less occurrence of side
effects of transdermal formulation compared to the oral one, and
this is in line with the final results. Third, we missed a control
group of patients without switch or free from anti-dementia
treatment (i.e. for side effects, loss of efficacy or no compliance).
Strength of the study was the design, comprehensive of cognitive
and psychiatric assessments at 6-month follow-up examinations.
In conclusion, results of this arm of the EVOLUTION study
suggests that, in mild to moderate AD patients with lack or loss of
efficacy and/or tolerability to one ChEI treatment, the switch to
another ChEI may represent an important tool in the therapeutic
treatment of cognitive and even affective symptoms. This
possibility should be better evaluated in further controlled studies.
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